{
    "name": "anthrax immune globulin",
    "comment": "Rx",
    "other_names": [
        "Anthrasil"
    ],
    "classes": [
        "Antidotes",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/anthrasil-anthrax-immune-globulin-1000012",
    "pregnancy": {
        "common": [
            "There are no human data to establish the presence or absence of associated risk during pregnancy or while breastfeeding"
        ],
        "specific": []
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Falsely high blood glucose levels",
                    "description": [
                        "Maltose in immune globulin products, including anthrax immune globulin, may give falsely high blood glucose levels with some blood point-of-care glucose testing systems (eg, those based on the GDH-PQQ or glucose-dye-oxidoreductase methods), possibly resulting in inappropriate administration of insulin and life-threatening hypoglycemia",
                        "To avoid interference by maltose, perform blood glucose measurements with a glucose-specific method (monitor and test strips)"
                    ]
                },
                {
                    "type": "Thrombosis",
                    "description": [
                        "May occur with immune globulin products",
                        "Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors",
                        "Thrombosis may also occur in the absence of known risk factors",
                        "For patients at risk of thrombosis, administer at the minimum infusion rate practicable",
                        "Ensure adequate hydration in patients before administration",
                        "Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "History of anaphylaxis or prior severe systemic reaction associated with the parenteral administration of this or other human immune globulin preparations",
                "IgA deficiency with antibodies against IgA and a history of IgA hypersensitivity, as it contains trace amounts of IgA (≤40 mcg/mL)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions may occur",
                "Contains maltose; may interfere with certain types of blood glucose monitoring systems (see Black Box Warnings)",
                "Thrombosis may occur following treatment with immune globulin products (see Black Box Warnings)",
                "Adverse reactions (eg, chills, fever, headache, nausea, vomiting) may be related to the rate of infusion; follow closely the recommended infusion rate",
                "Hemolytic anemia and hemolysis may develop; anthrax immune globulin may contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells with immune globulin, causing a positive direct antiglobulin reaction and hemolysis",
                "Aseptic meningitis syndrome, noncardiogenic pulmonary edema, and blood-borne infections may occur in association with administration of immune globulin products"
            ],
            "specific": [
                {
                    "type": "Renal impairment",
                    "description": [
                        "Acute renal dysfunction, acute renal failure, osmotic nephropathy, acute tubular necrosis, proximal tubular nephropathy, and death may occur upon use of immune globulin intravenous products",
                        "Caution with any degree of preexisting renal insufficiency and in patients at risk of developing renal insufficiency (including, but not limited to, those with diabetes mellitus, aged >65 yr, volume depletion, paraproteinemia, sepsis, and concurrent nephrotoxic drugs)",
                        "Administer at the minimum rate of infusion if practicable and ensure that patients are not volume depleted before infusion; do not exceed the recommended infusion rate",
                        "Assess renal function, including BUN and serum creatinine, before initiating and at appropriate intervals thereafter  If renal function deteriorates, consider discontinuing",
                        "Most cases of renal insufficiency following administration of immune globulin products have occurred in patients receiving total doses containing ≥400 mg/kg of sucrose; anthrax immune globulin does not contain sucrose"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "anthrax immune globulin decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "anthrax immune globulin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "anthrax immune globulin decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "anthrax immune globulin decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "anthrax immune globulin decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "anthrax immune globulin decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "anthrax immune globulin decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "anthrax immune globulin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "anthrax immune globulin decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "anthrax immune globulin decreases effects of yellow fever vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "anthrax immune globulin decreases effects of zoster vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "anthrax immune globulin decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "20.4"
        },
        {
            "name": "Nausea",
            "percent": "9.3"
        },
        {
            "name": "Infusion site pain",
            "percent": "9.3"
        },
        {
            "name": "Infusion site swelling",
            "percent": "7.4"
        },
        {
            "name": "Back pain",
            "percent": "3.7"
        }
    ]
}